TFF Pharmaceuticals to Participate in the 35th Annual Roth Conference
March 06, 2023 16:05 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, March 06, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer
February 08, 2023 16:05 ET
|
TFF Pharmaceuticals, Inc.
Dr. Harlan Weisman and recently appointed Chief Medical Officer Dr. Zamaneh Mikhak to Provide an Overview of the Corporate Strategy and 2023 Objectives Conference Call and Webcast Scheduled for...
TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer
January 09, 2023 08:00 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Leadership Transition
December 05, 2022 06:30 ET
|
TFF Pharmaceuticals, Inc.
Glenn Mattes to step down as Chief Executive Officer and as a Member of the Board of Directors Dr. Harlan F. Weisman, Vice Chairman of the Board, appointed as Interim Chief Executive Officer ...
TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering
November 29, 2022 16:01 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants
November 18, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
November 17, 2022 16:01 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 17, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022 16:01 ET
|
TFF Pharmaceuticals, Inc.
Clinical Proof-of-Concept Demonstrated in Compassionate Use in Two Case Studies with Voriconazole Inhalation Powder (TFF VORI) Growing Body of Peer-Reviewed Scientific Literature Provides...
TFF Pharmaceuticals to Hold Third Quarter 2022 Financial and Business Results Conference Call on November 14, 2022
November 07, 2022 16:05 ET
|
TFF Pharmaceuticals, Inc.
Company conference call and webcast at 4:30 PM ET FORT WORTH, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused...
TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics
November 03, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
Administration of dry powders will utilize Aptar Pharma’s Unidose (UDS) Powder Nasal Spray System The TFF dry powder vaccines maintain the antigen’s integrity, can be delivered to the targeted region...